Susceptibility testing
Susceptibility testing was performed using Sensititre panels (Trek Diagnostic Systems, Cleveland, OH) against the following antimicrobial agents:
• amikacin (AMI) The minimum inhibitory concentrations (MIC) and breakpoints were determined in accordance with guidelines established by the Clinical and Laboratory Standards Institute (CLSI) [16, 17] .
Data analysis
GraphPad Prism 5 software (GraphPad Software, Inc. La Jolla, CA) was used for statistical analysis.
Between 2002-2007, 578 Shigella isolates were received and confirmed by ProvLab. The overall 
Amoxicillin/ clavulanic acid Only 1.2% (n = 2) S. flexneri and 8.1% (n = 18) S. sonnei isolates were pan-susceptible to all antibiotics tested. All S. flexneri isolates were susceptible to AMI, GEN, AMC, KAN, FOX, TIO, AXO. All the S. sonnei were Table 2 resistant to AMP, CHL, NAL, STR, TET and SXT (Table 1) . When median MICs were analyzed for all agents the following changes were identified as in Table 2 . For S. flexneri median MICs were within two dilutions for most agents over the study period. Exceptions were for the following agents; AMP (increase), CHL (increase), SXT (increase and following drop), and SSS (decrease). For S. sonnei, median MICs were within two dilutions for most agents over the study period with the following exceptions; exception of AMP (decrease).
When data was combined for all years, the NAL and CIP resistance was 20.1% (33/164) and 14.9% (33/222) for S. flexneri and S. sonnei respectively. CIP resistance was identified only in S. flexneri isolates (4.9%, 8/164) when averaged over the six-year study period (Fisher's exact test, p = 0.001) (Figure 1a and 1b) [18, 19] . Data also suggests that azithromycin resistance may be emerging and resistance rates of 16% have been recently described in Bangladesh [20] . These studies indicate that travel to the Indian subcontinent, in patients returning to Western Canada with traveler's diarrhea should be determined to guide initial empiric treatment options; especially for severe infections because the association of S. flexneri and S. sonnei isolates from this region with fluoroquinolone and potential macrolide resistance [13, 21] . Although CIP resistance was described only in S. flexneri, we should remain vigilant for developing gyrA and parC mutations as well as the presence of plasmid mediated quinolone resistance determinants (PMQR) genes that may lead to increasing rates of CIP resistance in travel-related Shigella isolates which are beginning to emerge globally [4, 22] .
There are multiple factors that may have lead to CIP and NAL resistance in Shigella species originating from the Indian subcontinent [21] . It is possible that part of this emerging resistance may be associated with the increasing dominance of specific STs or clones of Shigella. Both this study and other work have identified a dominance of S. flexneri STs 2 and 6 in isolates of Indian origin and cases of traveler's diarrhea associated with the Indian subcontinent [23] . One factor driving multi-drug resistance in the Indian subcontinent may be the emergence of specific clones within these dominant STs [24] . Therefore, the identification of clonal groups within Alberta strains may be a powerful tool for tracking the development of drug-resistance in Shigella isolates from future cases of traveler's diarrhea.
